Gene Biotherapeutics (Gene Biotherapeutics) EV-to-Revenue : (As of Jun. 17, 2024)

Gene Biotherapeutics EV-to-Revenue Chart

Gene Biotherapeutics Annual Data
	Trend	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20
EV-to-Revenue		Get a 7-Day Free Trial					-	-	-	-	-

Gene Biotherapeutics Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Dec17	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
EV-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Gene Biotherapeutics's EV-to-Revenue

For the Biotechnology subindustry, Gene Biotherapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gene Biotherapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gene Biotherapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Gene Biotherapeutics's EV-to-Revenue falls into.

Gene Biotherapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Gene Biotherapeutics's EV-to-Revenue for today is calculated as:

Gene Biotherapeutics's current Enterprise Value is $0.00 Mil.
Gene Biotherapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gene Biotherapeutics  (OTCPK:CRXM) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Gene Biotherapeutics's PS Ratiofor today is calculated as:

Gene Biotherapeutics's share price for today is $0.0001.
Gene Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gene Biotherapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Gene Biotherapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Gene Biotherapeutics (Gene Biotherapeutics) Business Description